Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amid PD-1 Uncertainty, Bristol Under Pressure For M&A Activity

Executive Summary

Bristol says its checkpoint immunotherapies can hold the lead in renal cell carcinoma, despite increasing competition.


Related Content

Keytruda Is King, But Merck Faces Questions About Business Development
Pharma Q3 Results Preview: Merck Vs. Bristol In IO Showdown
Merck & Co.’s Keytruda/Inlyta Combo Invades Kidney Cancer Territory
Key Cancer Data To Be Unveiled At ESMO In Munich
Bristol Engineers An Oral TYK2 Inhibitor With Biologic-Like Efficacy That Rivals JAK Safety
First-Line Chemo Combo Data Help Merck's Keytruda Power Past Opdivo
Roche, Bristol On The Defensive After Merck's Lung Cancer Wins At ASCO
Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense
Stealthy NGM And Bristol Emerge As Serious NASH Competitors
Cardioxyl Buy To Resuscitate Bristol's CV Pipeline?


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts